A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis by D.K. Kochar, Govind Saini, S.K. Kochar, P. Sirohi, R.A. Bumb, R.D. Mehta,S.K. Purohit
Research Articles
J Vect Borne Dis 43, December 2006, pp. 161–167
A double blind, randomised placebo controlled trial of rifampicin with
omeprazole in the treatment of human cutaneous leishmaniasis
D.K. Kochara, Govind Sainia, S.K. Kochara, P. Sirohia, R.A. Bumbb, R.D. Mehtab,  &
S.K. Purohitc
aDepartment of Medicine, bDepartment of Skin and STD, S.P. Medical College, Bikaner; cDepartment of Preventive Medicine,
Veterinary College, Bikaner, Rajasthan, India
Abstract
Background & objectives: This study was conducted on 50 patients of Anthroponotic cutaneous
leishmaniasis (oriental sore) to assess the efficacy of rifampicin and omeprazole through a double
blind, randomised placebo control study.
Methods: The diagnosis of Anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica
was done by demonstration of  Leishmania tropica (LT) bodies from the painless, dry ulcerative lesion.
Each patient was assessed clinically in the beginning of the study, at the end of  2 ,4 and  6 weeks and
all observations were compared in both the groups. Twenty-five patients received rifampicin with
omeprazole (Group A) whereas other 25 patients received placebo (Group B) for a period of six weeks.
Results: Altogether 23 cases in group A and 21 cases in group B completed the study. About 16 (69.7%)
cases in group A and 3 (14.29%) cases in group B had complete healing, whereas 3 patients (13.04%)
of group A and 4 patients (19.05%) of group B had partial response and 4 patients (17.93%) of group
A and 14 patients (66.67%) of group B had no response at the end of study. The difference of two
groups was statistically highly significant (p<0.00025). All patients tolerated the drug and placebo very
well and no side effect was reported.
Interpretation & conclusion: In our opinion rifampicin and omeprazole is a highly effective, less toxic
and cheaper alternative for the management of cutaneous leishmaniasis.
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Introduction
Cutaneous leishmaniasis is a vector borne parasitic
disease caused by a number of different Leishmania
species. Following the bite of an infected sandfly the
clinical manifestations of the disease are largely gov-
erned by the characteristics of the infecting Leishma-
nia species. Infection can be limited to the skin or
mucous membrane in localised cutaneous leishma-
niasis (LCL), diffuse cutaneous leishmaniasis (DCL)
or mucosal leishmaniasis (ML)1.
Cutaneous leishmaniasis is prevalent in different
parts of India, but distribution of the disease is not
uniform. It has been reported from Bikaner (in the
northwest India) at endemic levels2-5. Studies carried162 J  VECT  BORNE  DIS  43, DECEMBER 2006
out in Rajasthan during 1971–73 revealed the ex-
istence of two clinicoepidemiological types—
(i) Anthroponotic cutaneous leishmaniasis (ACL)
restricted to urban areas, and (ii) zoonotic cutaneous
leishmaniasis (ZCL) restricted to rural areas. A long-
term follow-up study carried out during 1973–76 in
these foci revealed that ACL is caused by L. tropica
where man is a reservoir and man-to-man transmis-
sion is maintained by Phlebotomus sergenti. The dis-
ease is characterised by dry type of ulcer and ZCL is
caused by L. major, a naturally occurring infection of
Meriones hurriannae, a desert gerbil species main-
tained by P. salehi, a sandfly breeding in rodent bur-
rows. Human infections are occupational hazards and
are characterised by wet type of ulcers5,6. A clinical
study carried out in S.P. Medical College & PBM
Hospital, Bikaner during 1981–82 identified that
cases coming from Bikaner city area are only of dry
type and caused by L. tropica7. Recently Himachal
Pradesh has also been identified as a new endemic
focus of this disease in India8. The lesions are usual-
ly seen on the exposed parts of body such as face,
hands and legs and recovery after the treatment usu-
ally leaves a disfiguring dark coloured scar and pit-
ted area over the affected body parts9,10.
Different treatment regimens are available for the
management of cutaneous lesions. Many authors
have also advocated no treatment because of sponta-
neous healing which usually occurs after 6 months
from the onset of disease11,12. For many years, patients
had been treated with sodium stibogluconate, a pen-
tavalent antimonial compound but this treatment is
less than adequate because of prolonged intravenous
therapy, drug toxicity, and frequent need of hospital-
isation for the complete treatment course (usually 20
days). Pentamidine is also used as an alternative to
sodium stibogluconate. Intralesional berberine sul-
phate is also used but is more painful and leaves scars
after healing4.
Various oral medications such as ketoconazole, itra-
conazole, metronidazole, allopurinol, dapsone, etc.
have been used but their effects are not consistent. As
the prolonged injectable treatment modalities for
oriental sore are not well accepted by patients, and
other available oral drugs are not uniformly effective,
many workers have studied the effect of rifampicin
as an oral treatment for oriental sore and it had shown
some promising results13-17.  Moreover, omeprazole
has been found to be effective against Plasmodium
falciparum in vitro18. Rapid influx of H+ into the
everted vesicles of Leishmania species was found to
be dependent on the simultaneous presence of ade-
nosine-tri-phosphate (ATP) and Mg++. H+ entry into
the everted vesicles is strongly inhibited by omepra-
zole19. Taking these observations into account we
tried to assess the effect of combination of rifampi-
cin and omeprazole in the treatment of oriental sore.
Material & Methods
This study was conducted on randomly selected 50
cases of Anthroponotic cutaneous leishmaniasis.
Biopsies were taken from the edge of the skin lesions,
and were stained with Giemsa stain. The diagnosis
was confirmed by demonstration of LT bodies
(amastigote stage of L. tropica under oil immersion).
Informed consent was obtained from all adult partic-
ipants and from parents or legal guardians of minors.
The protocol was approved by the ethical committee
of the unit. One group of patients received rifampi-
cin (1200 mg/day) in two divided doses plus omepra-
zole 20 mg, whereas another group of patients re-
ceived placebo in a double blind controlled fashion
for 6 weeks. Detailed history and clinical examina-
tion including duration of disease, site, number, type
and distribution of lesions were noted in a proforma.
Laboratory investigations including haemoglobin
(Hb), total leukocyte count (TLC), differential leuko-
cyte count (DLC), serum bilirubin, serum aspartate
aminotransferase (AST), serum alanine aminotrans-
ferase (ALT) were done in every patient before start-
ing the treatment and at the end of 2, 4 and 6 weeks
after initiating treatment. All these data were collect-
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ble blind. At the end of 6 weeks, the files were decod-
ed, and the patients were divided into two groups—
Group A, receiving rifampicin and omeprazole and
group B receiving placebo. Clinical and parasitolog-
ical evaluations of the patients were performed again
at the end of the treatment period. The data were
collected on special proforma and MS-Excel was
used to tabulate the findings. Statistica 5.0 was used
to analyse the data. A cure was defined as complete
healing and disappearance of the lesion or reversible
hypopigmentation at the site of lesion. Incomplete or
partial healing was defined as a reduction in the size
of a lesion and the absence of parasites on smear.
Results
The present study was conducted on 50 cases of
Anthroponotic cutaneous leishmaniasis caused by L.
tropica who attended the associated group of hospi-
tal, Bikaner. The diagnosis was confirmed by demon-
stration of Leishmania tropica (LT) bodies from the
lesion. The LT bodies are the amastigotes form of
parasite in the Giemsa stained smear. It was observ-
ed that the amastigotes were heavily packed in the
mononuclear leucocytes, the cytoplasm was light
blue, nucleus appeared purple and the kinetoplast
appeared reddish purple. The nuclei in mononuclear
leukocyte were oval or globular in shape.
The details of cases of two groups are depicted in
Flow chart and Table 1. The ratio of male to female
was 2.13 : 1. Male predominance was probably due
to the habit of sleeping in open space outside the
house without mosquito nets and improper clothing
during night when the sandflies are active. Regard-
ing the type of lesion, erythematous nodular was the
most common type (40%) followed by erythematous
plaque (16%), erythematous ulcerative (14%), nod-
ular (12%), ulcerative (10%) and nodular ulcerative
(8%). Maximum cases were presented with 1–2
months of duration of disease. The differences in the
healing rates at the end of study between the two
groups were statistically significant. The Peto and
Peto Wilcoxon test compared two samples for the
entire period of the study. The patients who did not
show healing till the end of the study were censored.
About 20% patients had unhealed lesions in the group
receiving rifampicin and omeprazole whereas over
82% of patients had unhealed lesions at the end of 6
weeks in the group receiving placebo. Other details
are given in Table 1.
Discussion
Cutaneous leishmaniasis is being reported from al-
most every part of the world but it is commonly re-
Patient having multiple
lesions on the face (No-
dular type)
Same patient showing
complete healing after
treatment164 J  VECT  BORNE  DIS  43, DECEMBER 2006
Group A Group B Total
(Rifampicin + (Placebo) no. of
Omeprazole) patients
Male 17 17 34 (68%)
Female 8 8 16 (32%)
Age in years
16–20 12 10 22 (44%)
21–30 5 4 9 (18%)
31–40 4 5 9 (18%)
41–50 2 3 5 (10%)
51–60 2 2 4 (8%)
61–70 0 1 1 (2%)
Type of lesion
Erythematous nodular 11 9 20 (40%)
Erythematous plaque 3 5 8 (16%)
Ulcerative 3 2 5 (10%)
Erythematous ulcerative 2 5 7 (14%)
Nodular 4 2 6 (12%)
Nodular ulcerative 2 2 4 (8%)
Duration of disease in
months
0–1 2 6 8 (16%)
1–2 8 7 15 (30%)
2–3 5 5 10 (20%)
3–4 2 3 5 (10%)
4–5 1 0 1 (2%)
5–6 4 3 7 (14%)
(contd...)
6–8 1 0 1 (2%)
8–12 1 1 2 (4%)
>12 1 0 1 (2%)
Number of lesions
1 14 14 28 (56%)
2 5 7 12 (24%)
3 5 4 9 (18%)
>3 1 0 1 (2%)
Distribution of lesions*
Face 4 11 15 (30%)
Neck 3 2 5 (10%)
Arms 6 3 9 (18%)
Hand 9 6 15 (30%)
Back 2 2 4 (8%)
Abdomen 1 3 4 (8%)
Buttock 1 1 2 (4%)
Legs 4 3 7 (14%)
Foot 3 4 7 (14%)
Response to therapy
Complete healing 16 (69.57%) 3 (25.29%)
Partial response 3 (13.04%) 4 (19.05%)
No response 4 (17.39%) 14 (66.67%)
P-value 0.0007
Chi-square value 14.532
Group A Group B Total
(Rifampicin + (Placebo) no. of
Omeprazole) patients
ported from the area in and around Bikaner. Clinical
diagnosis is sometimes difficult, because occasional-
ly it resembles other skin diseases and the definitive
diagnosis is possible only by demonstration of organ-
isms from the lesion. Serological and leishmanian
skin tests become positive in 4–6 weeks, but they may
demonstrate cross-reactivity with other parasitic dis-
eases17. Serological testing is an insensitive means for
diagnosing cutaneous leishmaniasis because anti-
body titres are only minimally elevated, except in
patients who have diffuse cutaneous leishmaniasis20.
Depending on the availability of laboratory backup,
the species should be identified by molecular meth-
ods. All the cases in this study were diagnosed only
by demonstrating LT bodies from skin biopsy spec-
imen.
Table 1. Clinical characteristics of patients with cutaneous leishmaniasis
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There are very few options for the treatment of cuta-
neous leishmaniasis, and the commonly used treat-
ment with antimonial compounds that require daily
parenteral administration and frequent need of hos-
pitalisation. It is also associated with many adverse
effects, including those related to musculo-skeletal
symptoms, liver, bone marrow toxicity, pancreatitis
and electrocardiographic abnormalities. Intravenous
catheter related complications were also observed in
patients who were administered intravenous sodium
stibogluconate for 20 days21. A recent study of paren-
teral sodium stibogluconate therapy for cutaneous
leishmaniasis revealed complete healing of the le-
sions without scaring at the end of treatment. All
patients developed transient musculoskeletal symp-
toms and asymptomatic hepatitis17. Sodium stiboglu-
conate and berberine sulphate are also given locally,
however, these are painful and not acceptable to pa-
tients with multiple lesions4. Drug toxicity is also
very common with the use of pentamidine and am-
photericin B for the treatment of cutaneous leishma-
niasis.
In an earlier study, the use of metronidazole did not
show major clinical improvement in cutaneous leish-
maniasis22,23. A study from northern Algeria observed
good results with ketoconazole, but in other studies
it was almost entirely ineffective in patients with CL
caused by L. tropica and L. aethiopica24–27.
Rifampicin was used by various workers for manage-
ment of cutaneous leishmaniasis and showed some
promising results13,14,16. In one study, rifampicin
(1200 mg/day) was used in 46 patients and 41 pa-
tients showed complete healing13. However, many
other workers have questioned the efficacy of a short-
term course of rifampicin therapy28. The effect of
rifampicin is through its property of blocking RNA
synthesis by specifically binding and inhibiting DNA
dependent RNA polymerase. In a study from this in-
stitution on 46 patients in which 23 patients received
rifampicin 1200 mg/day in two divided doses and
another 23 received placebo for a period of 4 weeks,
those receiving drugs 17 (73.9%) had complete heal-
ing, 2 (8.6%) had partial healing and 4 (17.3%) had
no response, whereas in the placebo group 1 (4.3%)
had complete healing, 8 (34.8%) had partial healing
and 14 (60.9%) had no healing or exacerbation of
lesion. The difference was statistically significant and
the drug was well tolerated16.
Among the benzamidazoles, the omeprazole had
shown promising effect against Plasmodium falci-
parum in vitro18. It remains a possible and promising
therapeutic agent either alone or in combination, but
its effect on the Leishmania parasite was not available
even after extensive internet search. The rapid influx
of H+ into everted vesicles of Leishmania species was
found to be dependent on the simultaneous presence
of ATP (1 mM) and Mg++ (1 mM). H+ entry into evert-
ed vesicle was strongly inhibited by SCH28080
(IC50 = approximately 40 mM) and by omeprazole
(IC50 = approximately 50 mM), both of which were
characteristic inhibitors of mammalian gastric H+, K+
ATPase19. On this observation we thought to combine
rifampicin with omeprazole for the management of
cutaneous leishmaniasis.
At the end of the study we observed that out of 23
patients receiving rifampicin, 16 (69.6%) cases had
complete healing, 3 (13.04%) had partial healing and
4 (17.4%) had no healing whereas in the placebo
group 3 (14.2%) cases had complete healing, 4
(19.05%) had partial healing and 14 (66.7%) had no
healing. The difference was statistically significant
(p<0.05).
Thus, from the result of the present study it can be
safely concluded that rifampicin with omeprazole
was very effective, cheap, easily available and well-
tolerable oral alternative treatment for cutaneous
leishmaniasis. This short-term preliminary study pro-
vided some useful data about the efficacy of rifampi-
cin and omeprazole in cutaneous leishmaniasis and
thus provided the basis for further studies with larg-
er group of patients.166 J  VECT  BORNE  DIS  43, DECEMBER 2006
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